Forced expression of alpha-myosin heavy chain in the rabbit ventricle results in cardioprotection under cardiomyopathic conditions.
BACKGROUND
The biochemical differences between the 2 mammalian cardiac myosin heavy chains (MHCs), alpha-MHC and beta-MHC, are well described, but the physiological consequences of basal isoform expression and isoform shifts in response to altered cardiac load are not clearly understood. Mature human ventricle contains primarily the beta-MHC isoform. However, the alpha-MHC isoform can be detected in healthy human ventricle and appears to be significantly downregulated in failing hearts. The unique biochemical properties of the alpha-MHC isoform might offer functional advantages in a failing heart that is expressing only the beta-MHC isoform. This hypothesis cannot be tested in mice or rats because both species express alpha-MHC as the predominant isoform.


RESULTS
To test the effects of persistent alpha-MHC expression on the background of beta-MHC, we made transgenic (TG) rabbits that expressed rabbit alpha-MHC cDNA in the ventricle so that the endogenous myosin was partially replaced by the transgenically encoded species. Molecular, histological, and functional analyses showed no significant baseline effects in the TG rabbits compared with nontransgenic (NTG) littermates. To determine whether alpha-MHC expression afforded any advantages to stressed myocardium, a cohort of TG and NTG rabbits was subjected to rapid ventricular pacing. Although both the TG and NTG rabbits developed dilated cardiomyopathy, the TG rabbits had a higher shortening fraction, less septal thinning, and more normal +/-dP/dt than paced NTG rabbits.


CONCLUSIONS
Transgenic expression of alpha-MHC does not have any apparent detrimental effects under basal conditions and is cardioprotective in experimental tachycardia-induced cardiomyopathy.
James
Jeanne
J
Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Martin
Lisa
L
Krenz
Maike
M
Quatman
Carmen
C
Jones
Fred
F
Klevitsky
Raisa
R
Gulick
James
J
Robbins
Jeffrey
J
D000818:Animals; D030801:Animals, Genetically Modified; D002304:Cardiac Pacing, Artificial; D002311:Cardiomyopathy, Dilated / Q000209:etiology* / Q000235:genetics; D002316:Cardiotonic Agents; D015870:Gene Expression; D006352:Heart Ventricles / Q000378:metabolism*; D018995:Myosin Heavy Chains / Q000008:administration & dosage / Q000235:genetics*; D020033:Protein Isoforms / Q000235:genetics; D011817:Rabbits; D013312:Stress, Physiological; D013610:Tachycardia / Q000150:complications
D002316:Cardiotonic Agents; D020033:Protein Isoforms; D018995:Myosin Heavy Chains